Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib plus rituximab for previously treated indolent non-Hodgkin lymphoma
2012-004013-13Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in indolent lymphoma comparing Idelalisib + rituximab with Placebo + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Apr 2013; status: terminated.
02
Drugs
idelalisib
03
Conditions
indolent lymphoma
Beyond the preview
Go deeper on 2012-004013-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004013-13.